Literature DB >> 13678469

New HIV type 1 CRF01_AE/B recombinants displaying unique distribution of breakpoints from incident infections among injecting drug users in Thailand.

Artur Ramos1, Lily Nguyen, Dale J Hu, Suphak Vanichseni, Kachit Choopanya, Nancy L Young, Jordan W Tappero, Timothy D Mastro, Thomas M Folks, Shambavi Subbarao.   

Abstract

The goals of this study were to identify and characterize recombinant human immunodeficiency virus type 1 (HIV-1) genomes among incident infections in a prospective cohort study of injecting drug users (IDUs) in Bangkok, Thailand. Through cross-sectional, comparative phylogenetic analysis of the protease and env (C2-V4) gene regions, subtype discordance was observed in HIV-1 sequences from 4 of 111 IDUs (3.5%). Near-full-length HIV-1 genome sequences of the four strains revealed that in all four, the gp120 sequences clustered with a CRF01_AE prototype, while the remainder of the genomes displayed distinct mosaic patterns, with multiple breakpoints between HIV-1 CRF01_AE and subtype B-like regions. Two of the four HIV-1 recombinant strains displayed a nearly identical mosaic structure, suggesting the possible emergence and spread of a potentially new circulating recombinant form of HIV-1. Further characterization of these and other recombinant genomes through long-term follow-up will be important in understanding the generation of viral diversity and escape from the hosts immune responses. This information will be especially important for vaccine development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13678469     DOI: 10.1089/088922203322280892

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  7 in total

1.  Identification of a novel HIV type 1 circulating recombinant form (CRF52_01B) in Southeast Asia.

Authors:  Yongjian Liu; Lin Li; Zuoyi Bao; Hanping Li; Daomin Zhuang; Siyang Liu; Xiaolin Wang; Tianyi Li; Lei Jia; Shaomin Yang; Jingyun Li
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-05       Impact factor: 2.205

2.  CDC international HIV prevention research activities among injection drug users in Thailand and Russia.

Authors:  Alan E Greenberg; Jordan Tappero; Kachit Choopanya; Frits van Griensven; Mike Martin; Suphak Vanichseni; Scott Santibanez; Valerie Molotilov; Shannon Hader; Laura N Broyles
Journal:  J Urban Health       Date:  2005-09       Impact factor: 3.671

3.  CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic.

Authors:  Awet Abraha; Immaculate L Nankya; Richard Gibson; Korey Demers; Denis M Tebit; Elizabeth Johnston; David Katzenstein; Asna Siddiqui; Carolina Herrera; Lucia Fischetti; Robin J Shattock; Eric J Arts
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

Review 4.  Insights into the role of host genetic and T-cell factors in resistance to HIV transmission from studies of highly HIV-exposed Thais.

Authors:  Janet M McNicholl; Nattawan Promadej
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

5.  Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3'-azido-3'-deoxythymidine.

Authors:  Krista A Delviks-Frankenberry; Galina N Nikolenko; Frank Maldarelli; Saiki Hase; Yutaka Takebe; Vinay K Pathak
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

6.  Phylodynamics of HIV-1 from a phase III AIDS vaccine trial in Bangkok, Thailand.

Authors:  Marcos Pérez-Losada; David V Jobes; Faruk Sinangil; Keith A Crandall; Miguel Arenas; David Posada; Phillip W Berman
Journal:  PLoS One       Date:  2011-03-10       Impact factor: 3.240

Review 7.  Identification of conserved lentiviral sequences as landmarks of genomic flexibility.

Authors:  Maurice L J Moncany; Karine Dalet; Pascal R R Courtois
Journal:  C R Biol       Date:  2006-08-08       Impact factor: 1.583

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.